As the disease progresses, it’s important to regularly adapt treatment strategies based on consistent monitoring of BCR-ABL levels. This allows doctors to track the disease’s progression and ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

The small-molecule kinase inhibitor is designed to inhibit BCR-ABL gene fusion, which is the oncogenic driver of chronic myeloid leukemia (CML). In an ongoing phase 1 trial, 44% of 36 evaluable ...